Abstract:Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. Diagnosis: CML is characterized by a balanced genetic translocation, t (9;22) (q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR::ABL1 fusion oncogene, which in turn translates into a BCR::ABL1 oncoprotein. Frontline therapy: Four tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, bosutinib, and nilotinib are approved by the United States Food and Drug Administration for first-line treatment of newly diagnosed CML in chronic phase (CML-CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses but had no impact on survival prolongation, likely because of the availability of effective TKIs salvage therapies for patients who have a cytogenetic relapse with frontline TKI therapy. Salvage therapy: For CML post failure on frontline therapy, second-line options include second and third generation TKIs. Although potent and selective, these TKIs exhibit unique pharmacological profiles and response patterns relative to different patient and disease characteristics, such as patients' comorbidities, disease stage, and BCR::ABL1 mutational status. Patients who develop the T315I "gatekeeper" mutation display resistance to all currently available TKIs except ponatinib, asciminib, and olverembatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML-CP and failure (due to resistance) of at least two TKIs, and for all patients in advanced phase disease. Older patients who have a cytogenetic relapse post failure on all TKIs can maintain long-term survival if they continue a daily most effective/least toxic TKI, with or without the addition of non-TKI anti-CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, busulfan and others).

Systemic review on progress of drug therapy for chronic myelogenous leukemia

The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

Chronic myeloid leukemia:new development in therapy

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia

New Directions in the Biology and Therapy of Chronic Myeloid Leukemia

Pharmacotherapeutic Options for Philadelphia Chromosome-Positive CML

Progress of disease transformation and drug discontinuation in chronic myeloid leukemia

Treatment and diagnosis progress of chronic myeloid leukemia

[Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with BCR-ABL T315I Mutation--Review].

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia

Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia

The Molecular Mechanism of Chronic Myelogenous Leukemia and Its Therapeutic Implications: Studies in A Murine Model

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

New Insights into Antigen Specific Immunotherapy for Chronic Myeloid Leukemia

Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia

Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors

[The progress in classification and prognosis evaluation of BCR::ABL1 positive acute lymphoblastic leukemia]